ストックスクリーナーアプリを入手
16.86
2.32%
-0.40
プレマーケット:
16.86
前日終値:
$17.26
開ける：
$17.1
24時間の取引高:
1.13M
Relative Volume:
0.74
時価総額：
$1.13B
収益：
$796.00M
当期純損益:
$-136.49M
株価収益率:
-8.067
EPS:
-2.09
ネットキャッシュフロー:
$-64.24M
1週間 パフォーマンス:
-1.06%
1か月 パフォーマンス:
-14.46%
6か月 パフォーマンス:
-51.57%
1年 パフォーマンス:
-46.90%
1日の値動き範囲:
$16.53
$17.11
1週間の範囲:
$16.30
$17.73
52週間の値動き範囲:
$15.75
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
名前
Tandem Diabetes Care Inc
セクター
電話
858-366-6900
住所
12400 HIGH BLUFF DRIVE, San Diego, CA
TNDM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
16.86 | 1.13B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Mizuho | Neutral |
| 2025-03-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-03-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | 開始されました | Bernstein | Outperform |
| 2024-10-04 | 開始されました | Goldman | Neutral |
| 2024-10-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-08 | 開始されました | Canaccord Genuity | Buy |
| 2024-05-30 | 開始されました | Redburn Atlantic | Buy |
| 2024-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | アップグレード | Stifel | Hold → Buy |
| 2023-08-04 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-05-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-04-24 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | 開始されました | UBS | Neutral |
| 2023-01-26 | 開始されました | Wolfe Research | Peer Perform |
| 2022-11-15 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-08-09 | ダウングレード | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-25 | 開始されました | Barclays | Underweight |
| 2020-12-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | 開始されました | Wells Fargo | Overweight |
| 2020-07-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-06 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-18 | 繰り返されました | Raymond James | Outperform |
| 2020-04-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-03-05 | 開始されました | Citigroup | Neutral |
| 2020-02-06 | 開始されました | Raymond James | Outperform |
| 2020-02-04 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | 開始されました | Guggenheim | Buy |
| 2019-10-04 | アップグレード | UBS | Neutral → Buy |
| 2019-05-17 | 繰り返されました | BofA/Merrill | Neutral |
| 2019-05-13 | 開始されました | SVB Leerink | Outperform |
| 2019-03-08 | 開始されました | BMO Capital Markets | Outperform |
| 2019-03-05 | 繰り返されました | BofA/Merrill | Neutral |
| 2019-02-27 | 繰り返されました | Lake Street | Buy |
| 2018-11-21 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | 繰り返されました | Dougherty & Company | Buy |
| 2018-09-26 | 繰り返されました | Piper Jaffray | Overweight |
すべてを表示
Tandem Diabetes Care Inc (TNDM) 最新ニュース
When the Price of (TNDM) Talks, People Listen - news.stocktradersdaily.com
Reasons to Hold TNDM Stock in Your Portfolio for Now - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Capital Adjusts Tandem Diabetes (TNDM) Price Target Before Q - GuruFocus
RBC Cuts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Outperform Rating - marketscreener.com
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Mizuho Initiates Coverage of Tandem Diabetes Care (LSE:0M0F) with Neutral Recommendation - Nasdaq
Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last? - Yahoo Finance
Mizuho Initiates Coverage of Tandem Diabetes Care (TNDM) with Neutral Recommendation - Nasdaq
Forecasting The Future: 9 Analyst Projections For Tandem Diabetes Care - Benzinga
Mizuho Initiates Tandem Diabetes Care at Neutral With $20 Price Target - marketscreener.com
Mizuho sets Tandem Diabetes stock at Neutral with $20 target By Investing.com - Investing.com Canada
Mizuho Initiates Coverage of Tandem Diabetes (TNDM) with Neutral Rating | TNDM Stock News - GuruFocus
Tubeless Insulin Pump Market Set to Witness Significant Growth - openPR.com
SEC Form DEF 14A filed by Tandem Diabetes Care Inc. - Quantisnow
Diabetes Management Technologies Market Size, Report by 2034 - Precedence Research
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc.(TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Tandem Diabetes Care stock hits 52-week low at $17.61 By Investing.com - Investing.com Australia
Tandem Diabetes Care To Announce First Quarter 2025 Financial Results - MarketScreener
Diabetes Tech Giant Tandem to Reveal Q1 Performance: Key Metrics Coming April 30 - Stock Titan
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Tandem Diabetes Care stock hits 52-week low at $17.61 - Investing.com
(TNDM) Investment Analysis - news.stocktradersdaily.com
Prudential Financial Inc. Purchases 39,784 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
Tandem eyes Medicare coverage expansion for Type 2 - Yahoo Finance
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Artificial Pancreas Device System Market Projected To Witness - openPR
Tandem Diabetes Care Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution - simplywall.st
Tandem Diabetes Care Inc (TNDM) Stock Price Down 4.6% on Mar 26 - GuruFocus
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - Yahoo Finance
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology - MSN
Stifel maintains Tandem Diabetes Care stock Buy rating, $60 target By Investing.com - Investing.com UK
(TNDM) Long Term Investment Analysis - Stock Traders Daily
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock? - MSN
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights - Investing.com
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Tandem announces publication of results from trial of Control-IQ+ AID technology - Yahoo Finance
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - Yahoo Finance
Tandem’s Control-IQ+ looks like a smart move for insulin-using T2D - BioWorld MedTech
Tandem reports A1C reduction in type 2 diabetes study By Investing.com - Investing.com South Africa
Tandem Diabetes Launches Next-Gen Automated Insulin Delivery Algorithm in U.S. - MPO-mag
Tandem reports A1C reduction in type 2 diabetes study - Investing.com India
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes - Business Wire
Automated Insulin Delivery System Helps in Type 2 Diabetes - Medscape
Tubeless Insulin Pump Market Is Booming Worldwide | Medtronic - openPR
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery technology in the US - Marketscreener.com
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States - Enid News & Eagle
Tandem Diabetes Care Inc (TNDM) 財務データ
収益
当期純利益
現金流量
EPS
1.01%
0.46%
大文字化:
|
ボリューム (24 時間):